Meyka Pro banner
LifeMD, Inc.

LifeMD, Inc. (NASDAQ: LFMD) Stock Competitors & Peer Comparison

See LFMD's competitors and their performance on the NASDAQ and across the wider stock market.

LFMDNASDAQ
HealthcareMedical - Pharmaceuticals
$3.62
$0.06(1.69%)
U.S. Market opens in 12h 39m

Peer Comparison Table: Medical - Pharmaceuticals Industry

Detailed financial metrics including price, market cap, P/E ratio, and more for LFMD and its NASDAQ peers.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
LFMD$3.56+4.71%172.2M-7.12-$0.50N/A
RPRX$56.77-0.86%25.2B10.81$5.25+1.60%
CORT$110.77+2.61%12B316.49$0.35N/A
WBA$11.98+0.50%10.4B-1.64-$7.29+4.17%
LQDA$90.22+0.89%8B644.43$0.14N/A
KNSA$76.06-0.59%5.8B84.51$0.90N/A
TRLV$8.75-2.78%1.5B-20.83-$0.42N/A
HROWL$25.61+0.19%1.4BN/AN/AN/A
HROWM$26.03-0.08%1.3BN/AN/AN/A
CUVL$6.68-0.65%336.6MN/AN/AN/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

Royalty Pharma plc (NASDAQ: RPRX)

LFMD vs RPRX Comparison August 2026

LifeMD, Inc. (NASDAQ: LFMD) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFMD stands at 172.2M. In comparison, RPRX has a market cap of 25.2B. Regarding current trading prices, LFMD is priced at $3.56 on the NASDAQ, while RPRX trades at $56.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFMD currently has a P/E ratio of -7.12, whereas RPRX's P/E ratio is 10.81. In terms of profitability, LFMD's ROE is -1.79%, compared to RPRX's ROE of +0.11%. Regarding short-term risk, LFMD is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for LFMD.Check RPRX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions